Contemporary reconstructive vascular techniques can be safely used to permit resection of tumors invading major vascular structures.
resected and reconstructed. Iliac, femoral, or popliteal reconstructions were performed in 15 patients (31.3%). Portal vein reconstruction was performed to permit resection of pancreatic neoplasms in 8 patients (16.7%). Resection and reconstruction of either a brachiocephalic vessel or superior vena cava was performed in 4 patients. Thirty-day mortality was 2.1%, as 1 patient died of a myocardial infarction following tumor resection with vascular reconstruction. Overall 30-day morbidity was 12.2%. Early vascular morbidity included bleeding from an arterial anastomosis and a compartment syndrome requiring fasciotomy. Primary patency of the vascular reconstructions at 24 months was 90% and tumor-free survival was 70%. Thirty-one patients (63%) were alive, without tumor recurrence and with a patent vascular reconstruction at 24 months. No patient died or lost a limb due to occlusion of the vascular reconstruction.
Conclusion: Contemporary reconstructive vascular procedures permit resection of tumors that involve major vascular structures with acceptable early and late morbidity and mortality.
Arch Surg. 2002; 137:901-907 O VER THE past few decades the postoperative morbidity and mortality following a major oncologic resection have steadily declined. 1, 2 With this improvement in surgical outcomes, many surgeons have liberalized the indications for resection of selected tumors to include those with invasion of critical vascular structures that require concomitant vascular reconstruction. 3, 4 Although several surgeons have reported favorable outcomes for such an approach in selected lower extremity sarcomas, head and neck neoplasms, pancreatic neoplasms, and testicular carcinomas, others have raised concern that postoperative vascular morbidity and mortality are excessive. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] In ad-dition, little is known concerning the late vascular morbidity of reconstructions performed at the time of tumor resection, including the incidence of occlusion of the vascular reconstruction or graft as well as associated limb loss or death due to such vascular events. To investigate these issues, a review of our institutional experience with these extended oncologic procedures was performed to (1) examine the perioperative morbidity and mortality of an en bloc tumor excision requiring a major vascular resection and reconstruction, (2) define patient and tumor-free survival following such procedures, and (3) assess the early and late vascular morbidity and mortality of the major vascular resection and reconstruction and its effect on survival.
RESULTS
Forty-nine patients (37 males and 12 females) with ages ranging from 15 to 80 years (mean age, 55 years) under-went an oncologic procedure that required a concomitant vascular resection and reconstruction due to invasion or adherence of the neoplasm to a major vascular structure. Medical cormorbid conditions included hypertension in 8 patients (16%), diabetes mellitus in 3 patients (6.0%), known coronary artery disease in 3 patients (6.0%), and chronic obstructive pulmonary disease in 2 patients (4.1%). The pathology of the tumor resected included the abdominopelvic (34 patients), extremity (11 patients), thoracic (3 patients), and neck (1 patient) malignancies listed in Table 1 . The oncologic procedure was the initial attempt at tumor resection in 42 patients and performed for recurrence of a previously resected neoplasm in 7 patients.
Vascular reconstructions included infrarenal (18 patients), juxtarenal (1 patient), or suprarenal (1 patient) aortic resections with prosthetic graft reconstruction in 20 patients (41.7%). Inferior vena cava resection with ringed polytetrafluoroethylene [PTFE] graft reconstruction was used in 6 patients (12.5%). Five patients (10.4%) had both the infrarenal aorta and inferior vena cava resected and reconstructed. Iliac or lower extremity reconstructions were performed in 15 patients (31.3%) using 
PATIENTS AND METHODS
Patients at University of Southern California (USC)affiliatedhospitals(USCUniversityHospital,NorrisCancer Institute, Los Angeles County-USC Medical Center) between January 1, 1987, and December 31, 2001, who required a concomitant resection of a major vascularstructureandvascularreconstructioninanattempt to achieve complete tumor resection were identified by query of the USC Vascular Registry. Those patients who underwent vascular resection or ligation, vascular intervention for injury to vessels during an oncologic procedure,resectionofnoncriticalornonaxialvascularstructures that did not require reconstruction, or whose vascular procedure was performed for reasons other than tumor resection, that is, concomitant abdominal aortic or iliac aneurysms, were excluded.
The vascular resections and reconstructions were performed using standard operative techniques. Control of involved vascular structures proximal and distal to the tumor mass was accomplished prior to en bloc resection of the tumor with involved vasculature. Patients received systemic heparin sodium prior to resection of the tumor specimen and division of the involved vascular structures. Vascular reconstructions were tailored to the vessels involved and used a variety of vascular grafts.
Medical records were reviewed to delineate the operative procedure, vascular graft used, pathology of the tumor, and perioperative and postoperative morbidity and mortality. Late survival and tumor recurrence were determined and characterized by review of clinical records and pathology reports. Patency of the vascular reconstruction was determined by review of follow-up duplex sonograms, computed tomographic scans, and clinical examinations. The main outcome measures were early (Ͻ30 days) morbidity and mortality, late (Ͼ30 days) vascular morbidity and mortality, primary patency of the vascular reconstruction, and tumor-free survival.
A 2-tailed Fisher exact test and 95% confidence intervals were used to evaluate the risk of postoperative complications for the following variables: age, sex, any comorbid medical condition, graft type, aortic and/or inferior vena cava procedure, tumor location, and resection margins positive for tumor and/or nodal and/or distant metastases present in the resected specimen. Actuarial estimates of tumor-free survival and primary patency of the vascular reconstruction were derived using life-table methods. For these analyses, imaging or clinical evidence of occlusion of the reconstruction or hemodynamically significant stenosis of a graft that required repair was considered a failure of the vascular reconstruction. Evidence of tumor recurrence or death by any cause was used to determine tumor-free survival. The SAS statistical software (The SAS System, Release 8.2; SAS Institute Inc, Cary, NC) was used for statistical analysis.
both autogenous and prosthetic grafts. To permit resection of a pancreatic neoplasm, portal vein reconstruction by primary anastomosis or autogenous graft was performed in 8 patients (16.7%). Vascular resection and reconstruction for tumor invasion of the carotid (interposition saphenous vein graft), subclavian (PTFE), superior vena cava (superior vena cava to internal jugular vein), and innominate artery (PTFE) were each performed on 1 occasion.
Pathologic examination of the resected specimen documented incomplete tumor resection with positive margins in 2 patients, positive nodal metastases in the surrounding node-bearing soft tissues in 3 patients, and distant metastatic disease that was resected along with the primary neoplasm in 5 patients. Tumor type of the distant metastatic disease was testicular (3 patients), fallopian (1 patient), and carcinoid (1 patient).
Overall 30-day mortality was 2.1% as 1 patient died on postoperative day 5 due to a myocardial infarction that followed resection of the infrarenal aorta, vena cava, and a renal clear cell adenocarcinoma. Thirty-day morbidity was 12.2% and included 2 wound infections, 1 hematoma requiring drainage, and 1 episode of combined sepsis, adult respiratory distress syndrome, and a chylothorax. Two complications occurred related to the vascular procedures performed. In 1 patient, significant bleeding on the third postoperative day from an anastomosis of a femoropopliteal bypass graft necessitated urgent exploratory surgery and repair. A second patient developed a compartment syndrome that required a fasciotomy after en bloc resection of a large, bulky testicular neoplasm that had invaded both the aorta and inferior vena cava. Ultimately, the patient had a residual peroneal nerve palsy requiring the long-term use of an orthotic device. The odds ratio for the risk of postoperative morbidity or mortality were greater than 2.5 in those patients with positive margins or nodal and/or metastatic disease at the time of the operation ( Table 2 ). The odds ratios were less than 2.0 for age, any comorbid medical condition, sex, graft type, aortic and/or caval reconstruction, and tumor location.
Mean follow-up was 19.1 months (median followup, 24 months). Late vascular morbidity occurred in 5 patients (10%). One patient experienced thrombosis of a saphenous vein graft used to reconstruct the superficial femoral artery 4 months after resection of an extremity sarcoma. This required a femoropopliteal bypass that remains patent at 3 months. Another patient following resection of an extremity sarcoma developed at 2 months a long segment stenosis in the saphenous vein used to reconstruct the superficial femoral artery. A graft revision of interposition vein was successfully performed. In another patient an iliofemoral reconstruction with PTFE occluded 8 months after resection of a recurrent transitional cell carcinoma. A femoral-femoral ringed PTFE bypass was performed that remained patent for an additional 26 months. A fourth patient experienced the occlusion of a limb of an aortobiiliac graft placed 10 years earlier for resection of a testicular tumor. Patency of the graft was reestablished by thrombolysis. The limb remains patent 14 months later. The final patient developed significant lower extremity edema and pain when a ringed PTFE graft used to reconstruct the iliofemoral vein thrombosed 12 months after re-section of a chondrosarcoma. Concomitantly, the patient developed a local recurrence of the chondrosarcoma that required hemipelvectomy.
Follow-up duplex sonograms (13 patients), contrastenhanced computed tomographic scans (26 patients), or follow-up clinical examinations (9 patients) were used in 48 patients (98.0%) to document patency of the vascular reconstruction. One patient who was lost to follow-up after the immediate postoperative period is excluded from this analysis. For the 9 patients who underwent only a clinical examination, patency of the vascular reconstruction was inferred by absence on clinical evaluation of extremity edema, critical limb ischemia, and absent or diminished extremity pulses or abdominal pain. Actuarial estimates of primary patency at 12 and 24 months were 93% and 90%, respectively (Figure 1) .
Eleven patients (22.9%) developed locoregional recurrence of the resected neoplasm during the course of follow-up. Recurrent tumors included 5 extremityacetabular sarcomas, 3 testicular carcinomas, 1 fallopian adenocarcinoma, 1 extremity melanoma, and 1 pancreatic adenocarcinoma. Recurrence of testicular carcinoma (3 patients), fallopian adenocarcinoma (1 patient), osteogenic carcinoma (1 patient), leiomyosarcoma (1 patient), pancreatic adenocarcinoma (1 patient), and melanoma (1 patient) led to the deaths of 8 patients. Actuarial life-table estimates of tumor-free survival at 12 months was 95% and at 24 months was 70% (Figure 2) . At 24 months, 31 (63%) of the 49 patients were alive, free of recurrent tumor with primary patency of the vascular reconstruction (Figure 3 ). This was not statistically different from tumor-free survival alone at the same time point (P=.32).
COMMENT
Current vascular techniques permit reconstruction of major vascular structures with a high degree of reliability and durability. [1] [2] [3] [4] [5] [6] [7] [8] Despite the recognized success of vascular reconstructions, particularly for major abdominal and thoracic vessels, many surgeons still consider tumor invasion of critical vascular structures a relative contraindication to tumor removal. 1, 11 The current study was performed to determine the short-term and long-term vas-cular morbidity and mortality associated with resection of neoplasms that are adherent to critical, major vascular structures. The surgical literature includes many studies that describe the outcomes for tumors requiring a concomitant major vascular resection and reconstruction. Kelly et al 6 described 6 patients with large testicular tumors that required en bloc aortic resection and reconstruction for complete tumor resection with no associated vascular-related complications. Vena cava reconstruction for a variety of retroperitoneal tumors was shown by Bower et al 12 to be associated with minimal early vascular morbidity and a graft patency of greater than 80% at 24 months. Pedrazzoli et al 1 reviewed 22 studies, encompassing 841 patients with pancreatic cancer who required portal vein resection and reconstruction at the time of pancreaticoduodenectomy. Their analysis demonstrated that the addition of a portal vein resection and reconstruction added little to the morbidity and mortality of pancreaticoduodenectomy. Wright et al 3 reported only 1 major carotid complication in 20 patients undergoing oncologic resections that required carotid resection and reconstruction. Koperna et al 5 found that vascular morbidity was 21% in 13 patients who underwent resections of lower extremity sarcomas that required vascular resection and reconstruction. However, late graft complications were few and limb salvage was possible in patients who otherwise would have required amputation. In contrast, to these favorable reports, Bianchi et al 7 found morbidity and mortality to be significant and substantially increased in patients undergoing a variety of oncologic and concomitant vascular procedures at their institution. However, this report includes not only patients undergoing elective resection of tumors involving vascular structures, but also patients who required a "rescue" vascular procedure to address either a postoperative vascular complication or an unplanned injury to a critical vascular structure at the time of tumor resection. Similar to the report by Bianchi et al, 7 the current study analyzes a single institutional experience in which several vascular techniques were applied to permit resection of a diverse group of neoplasms. Unlike the report by Bianchi et al, 7 our study includes only patients undergoing an elective resection and is not concerned with those in whom a vascular procedure was performed to manage an intraoperative or postoperative vascular complication. We found in this defined patient population that vascular-related morbidity and mortality were uncommon and overall early complications were comparable to that reported for resection of the tumor alone. Furthermore, analysis of several preoperative and operative variables failed to document a relative increase in complications for aortic or vena caval procedures as well as the various grafts used. Evidence of positive margins and/or nodal or metastatic disease was the only variable with an odds ratio greater than 2.5 that, although not statistically significant, is suggestive of a relative increase in the risk of postoperative complications when compared with the other variables considered.
Another potential concern of any vascular reconstruction is late failure with compromise to vital structures or limb loss. Late vascular morbidity did occur with failure of 4 vascular reconstructions within the first 12 months and a graft limb thrombosis occurring at 10 years. Of the 5 late vascular complications, 4 were successfully managed by placement of another vascular graft or endovascular intervention. The remaining patient had tumor recurrence in temporal proximity to the graft occlusion. Hemipelvectomy for oncologic indications accounted for the patient's limb loss. Overall, patency of the vascular reconstructions was 90% at 24 months. But more importantly, early or late vascular complications were not responsible for any observed limb loss or death.
The primary value of an oncologic procedure can be measured in tumor-free survival. Overall tumor-free survival was 70% at 24 months and for selected tumors either similar or somewhat different than that reported in the literature. With a follow-up of 1 month to 16 years, Spitz et al 13 reported 52.6% of patients were disease free after resection of bulky testicular tumors that required concomitant caval resection. In the present series, diseasefree survival for patients with testicular tumors was 77% (3 patients). All 3 deaths were due to tumor recurrence including 1 in a patient with a radioresistant seminoma (Ͻ2% of seminomas). In reports by Koperna et al 5 and Karakousis et al, 8 local recurrence rates for lower extremity sarcomas were found to be 6% and 0%, respectively. Koperna et al 5 noted a mortality rate of 30.8% due to development of metastatic disease. Of the 11 lower extremity sarcomas, 3 (27.3%) recurred in this study, and 3 patients (27.3%) died of distant metastatic disease. The collective review of Pedrazzolli et al 1 of patients undergoing portal vein resection and reconstruction at time of pancreaticoduodenectomy documented a 5-year survival of 6%. Of the 7 patients in the present study only 1 patient (20.8%) had developed recurrent disease at the time of this article. This unexpected result may be because of the highly select nature of these 7 patients, since they represent less than 10% of patients subjected to pancreaticoduodenectomy at our institution over the past 4 years. Also, the ad-dition of portal vein resection during pancreaticoduodenectomy has only recently been introduced at our institution, resulting in limited patient follow-up. The expectation is that with longer follow-up, the incidence of recurrent disease will increase. [14] [15] [16] If this fails to occur, the potential factors that may be responsible for improved survival will need to be further investigated.
When performing a vascular resection and reconstruction as part of an oncologic procedure, the additional late morbidity that may occur with failure of the reconstruction can be analyzed by constructing a life table where tumor recurrence or failure of a vascular reconstruction is a primary end point. Whereas tumor-free survival was 70% at 24 months the addition of failure of the vascular reconstruction decreased the favorable outcome to 63%. Since this small decrease failed to achieve statistical significance, it adds further support to the conclusion that the additional morbidity and mortality of the vascular procedure have little influence on long-term outcome. This conclusion, however, should be viewed in the context of the limitations of the present study. First, as for most studies of this nature, the sample size is small and the method is retrospective, which makes any statistical analysis less certain. Second, in 9 patients who did not have an objective imaging study to document patency of the vascular reconstruction, clinical examination alone was the determinant. However, since all vessels included in the study were major axial vessels that would cause morbidity usually not missed by an experienced observer, it is unlikely that many vascular failures went unrecognized.
Invasion of major vascular structures has been considered by some a barrier to the removal of large neoplasms. The results reported herein support the contrary contention that the need for resection and reconstruction of a major vascular structure should not prohibit the resection of any given tumor. The study demonstrates that most major vascular reconstructions performed in this setting have a high degree of success, do not appreciably increase overall early morbidity and mortality, and have little influence on long-term outcome. Although late graft occlusions can occur, most can be managed successfully and do not result in death or limb loss. In essence, long-term patient outcome is not determined by the need to perform a concomitant vascular procedure but rather by the biological behavior of the resected malignancy.
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